ADD2 rs3755351 — Beta-Adducin and the Renal Sodium Set Point
Beta-adducin11 Beta-adducin
encoded by ADD2, one of three adducin subunit genes (ADD1, ADD2, ADD3) is a cytoskeletal protein that
heterodimerizes with alpha-adducin to regulate the cortical actin
network beneath the plasma membrane of renal tubular epithelial cells.
The adducin complex controls how efficiently the sodium-potassium pump
(Na+/K+-ATPase) is recycled to and from the cell surface — a mechanism
that sets the kidney's baseline rate of sodium reabsorption and, by
extension, blood pressure. The intronic variant rs3755351 emerged from the
first large-scale Japanese hypertension GWAS as the single SNP with the
strongest statistical signal in the entire genome-wide screen.
The Mechanism
In renal proximal tubule cells, adducin anchors Na+/K+-ATPase pumps to
the clathrin-mediated endocytic machinery.
Normal constitutive endocytosis22 Normal constitutive endocytosis
the baseline recycling of membrane proteins into the cell interior
continuously removes a proportion of Na+/K+-ATPase from the cell surface,
limiting how much sodium the kidney retakes from the filtrate.
Hypertension-associated adducin variants reduce this constitutive
endocytosis, keeping more pumps at the membrane and increasing sodium
reabsorption — a subtle but persistent upward shift in the blood pressure
set point.
rs3755351 lies within an intron of ADD2. Because ADD2 produces multiple
splicing isoforms33 splicing isoforms
different mRNA transcripts from the same gene by including or excluding different exon segments
with distinct expression levels in kidney and brain, intronic variants
can alter splice-site strength, exon inclusion rates, or regulatory
element binding — changing effective ADD2 protein levels in the tissues
where blood pressure is set. The precise molecular consequence of
rs3755351 has not been characterized at the protein level; its biological
plausibility rests on the well-established role of adducin in renal
sodium handling and the convergent evidence from the Milan hypertensive
rat model.
The Evidence
Kato et al. 200844 Kato et al. 2008 performed a three-tiered genome-wide association study in Japanese subjects (up to 619 hypertensive and 1,406 normotensive individuals in the final tier) and found rs3755351 carried the lowest p-value of all 75 candidate SNPs selected from an initial screen of 80,795 markers (combined p = 1.7×10⁻⁵). The authors explicitly noted that ADD2 was "nominated" as a susceptibility gene for hypertension, pending independent replication.
Mechanistic support comes from cell biology. Torielli et al. 200855 Torielli et al. 2008 demonstrated in renal epithelial cell lines that alpha-adducin mutations reduce constitutive Na+/K+-ATPase endocytosis and that adducin associates directly with clathrin-coated vesicles involved in pump internalization. Bianchi 200566 Bianchi 2005 reviewed the full translational chain from Milan hypertensive rats (which carry adducin mutations) to human association data, describing how adducin polymorphisms increase tubular sodium reabsorption.
A replication attempt in an African-Brazilian quilombo population77 African-Brazilian quilombo population (652 individuals from 97 families) found no significant individual association of rs3755351 with blood pressure. This population-specific null result, combined with the absence of any GWAS Catalog registration for rs3755351, means the hypertension association remains a single-study nomination with limited independent confirmation.
Evidence level is therefore emerging: mechanistically credible, with one genome-wide signal in a specific ancestry group and no large cross-ancestry meta-analytic validation.
Practical Implications
Because rs3755351 is an intronic variant in ADD2 without established clinical utility, carriers of the T allele cannot currently receive guideline-supported medication adjustments based on this SNP alone. The actionable guidance centers on monitoring blood pressure trends.